Abbott Laboratories SEC filings document an Illinois healthcare company with common shares listed under ABT and operations in diagnostics, medical devices, nutritionals and branded generic medicines. The filings include Form 8-K reports on operating results, non-GAAP financial measures, material agreements, acquisition-related events, debt financing and amendments to corporate governance documents.
Abbott's proxy and event filings cover shareholder voting matters, board and bylaw governance, executive compensation, capital-structure disclosures and clinical or regulatory disclosures. The filing record also documents the completed Exact Sciences acquisition and the addition of cancer diagnostics to Abbott's broader diagnostic portfolio.
Blount Sally E. reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES director Sally E. Blount received a grant of 2,286 restricted stock units under the Abbott Laboratories 2017 Incentive Stock Program. Each unit will be paid in one Abbott common share on the earlier of her separation from service, death, or a defined change in control. Following this award, she holds 36,344 common shares directly.
Babineaux-Fontenot Claire reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES director Claire Babineaux-Fontenot received a grant of 2,286 common shares on April 24, 2026, recorded at a price of $0.00 per share, as a stock-based award. Following this grant, she directly holds 7,603 Abbott common shares.
The award is structured as restricted stock units under the Abbott Laboratories 2026 Incentive Stock Program. According to the terms, the units will be settled on a one-for-one basis in Abbott common shares upon the earlier of her separation from service, death, or a change in control as defined in the program.
Ahuja Nita reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director Nita Ahuja received an equity award of 2,286 common shares-equivalent as a restricted stock unit grant. The award was granted at a price of $0.00 per share under the Abbott Laboratories 2026 Incentive Stock Program.
The units will be settled in Abbott common shares on a one-to-one basis upon the earlier of the director’s separation from service, death, or a change in control as defined in the program. Following this grant, Ahuja’s reported direct holdings total 2,286 common shares.
ABT reported a Form 144 notice to sell restricted stock units tied to multiple grant dates. The filing lists planned dispositions by grant date ranging from 04/24/2009 to 04/25/2025, with per‑grant counts such as 2,465, 2,108, and others shown on the form.
The seller is recorded through UBS Financial Services, Inc. at the listed address and the filing date is 04/27/2026. The securities are Common stock registered on the NYSE.
Abbott Laboratories EVP and CFO Philip P. Boudreau reported multiple common share holdings and transactions dated April 23, 2026. A key event was an open-market purchase of 2,200 common shares at $91.50 per share, held indirectly through his spouse.
The filing also shows a discretionary transaction under Rule 16b-3(f) involving 8,909 common shares at $92.04 per share in a profit sharing trust, bringing that trust’s balance to 9,276 shares as of that date. Separately, Boudreau reports 71,172 common shares held directly after these transactions.
Abbott Laboratories reported that shareholders approved its new 2026 Incentive Stock Program, authorizing up to 140,000,000 common shares for equity-based awards. The plan lets the company grant stock options, restricted stock, restricted stock units, performance awards and other share-based incentives to employees and non-employee directors.
Kevin Conroy was named to Abbott’s Board of Directors, and the board size was increased from twelve to thirteen members effective April 24, 2026. Shareholders also elected the director slate and approved routine governance matters at the annual meeting.
Abbott Laboratories reported first-quarter 2026 results that met its internal expectations and highlighted a major expansion into oncology diagnostics. Net sales were $11.164 billion, up 7.8% year over year, with comparable sales growth of 3.7% after adjusting for foreign exchange, the Exact Sciences acquisition and a structural heart agreement.
GAAP net earnings were $1.077 billion and diluted EPS was $0.61, both down about 19% from a year ago, driven by higher operating costs and acquisition-related charges. Excluding specified items, adjusted net earnings rose to $2.022 billion, and adjusted diluted EPS increased 6% to $1.15.
Medical Devices led growth with reported sales up 13.2%, while Diagnostics rose 6.1% and Established Pharmaceuticals 13.2%; Nutrition declined 6.0% as Abbott reset pricing and volumes. On March 23, 2026, Abbott completed its acquisition of Exact Sciences, creating a new Cancer Diagnostics business built around Cologuard and the Cancerguard multi-cancer screening test.
Abbott now projects full-year 2026 comparable sales growth of 6.5%–7.5% and adjusted diluted EPS of $5.38–$5.58, including $0.20 of dilution from the Exact Sciences deal. It also guided second‑quarter 2026 adjusted diluted EPS to $1.25–$1.31 and declared its 409th consecutive quarterly dividend of $0.63 per share.
ABBOTT LABORATORIES director John G. Stratton received a grant of 382 stock equivalent units as board compensation. The units were credited on the basis of a reference price of $102.67 per unit and are held in a stock equivalent unit account under a grantor trust established by the director.
The stock equivalent units are paid in cash, generally at age 65 or upon retirement from the board, and earn the same return as if the fees were invested in Abbott common shares, including a dividend reinvestment feature. Following this award, Stratton’s balance in the account totals 13,489 stock equivalent units. This is a non‑market, compensation-related acquisition rather than an open-market share purchase or sale.
ABBOTT LABORATORIES director Michael F. Roman received a grant of 367 stock equivalent units on Abbott shares as part of his director compensation. These units are credited to a stock equivalent unit account and are generally paid in cash at about age 65 or upon retirement from the board. Following this award, his balance totals 6,283 stock equivalent units, which earn the same return as if the underlying fees were invested in Abbott common shares, including units acquired through a dividend reinvestment feature.